Exenatide (synthetic exendin-4) significantly reduced A1C in patients with type 2 diabetes who were failing maximum doses of a sulfonylurea, according to researchers at the University of North Carolina School of Medicine in Chapel Hill, North Carolina, and the Veterans Medical Center at the University of California San Diego. Exenatide was well tolerated and associated with weight loss.
In a 30-week study conducted at 101 sites in the United States, 377 subjects were randomized to receive exenatide injected subcutaneously twice daily (before breakfast and dinner) or placebo.
The most common adverse events were generally mild or moderate and gastrointestinal in nature. No severe hypoglycemia was observed.